These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 38243154)

  • 1. Biosimilars in IBD: What Every Clinician Needs to Know.
    Angyal A; Bhat S
    Curr Gastroenterol Rep; 2024 Mar; 26(3):77-85. PubMed ID: 38243154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
    Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 4. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.
    Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL
    Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Guide to Navigating the Landscape of Biosimilars for Inflammatory Bowel Disease.
    Bhat S; Kane SV
    Gastroenterol Hepatol (N Y); 2024 Jul; 20(7):376-382. PubMed ID: 39206027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in IBD: from theory to practice.
    Danese S; Bonovas S; Peyrin-Biroulet L
    Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease.
    Bhat S; Limdi JK; Cross RK; Farraye FA
    Dig Dis Sci; 2021 Aug; 66(8):2513-2532. PubMed ID: 34176024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease.
    Rusch C; Wood M; Kennedy AG; Tompkins BJ; Frasca JD
    J Clin Pharm Ther; 2022 Nov; 47(11):1851-1857. PubMed ID: 36134561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in Inflammatory Bowel Disease.
    Buchner AM; Schneider Y; Lichtenstein GR
    Am J Gastroenterol; 2021 Jan; 116(1):45-56. PubMed ID: 33110013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
    Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
    Kim H; Alten R; Avedano L; Dignass A; Gomollón F; Greveson K; Halfvarson J; Irving PM; Jahnsen J; Lakatos PL; Lee J; Makri S; Parker B; Peyrin-Biroulet L; Schreiber S; Simoens S; Westhovens R; Danese S; Jeong JH
    Drugs; 2020 Feb; 80(2):99-113. PubMed ID: 32002851
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.